Bortezomib in Treating Patients With Lymphoproliferative Disorders
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have
low-grade lymphoproliferative disorders. Bortezomib may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth.